Further research indicated that high expression of COMMD6 is associated with shorter survival in HNSC, cholangiocarcinoma, and ACC patients, but it correlates with longer survival in LGG, uveal melanoma, testicular germ cell tumors, thyroid carcinoma, and uterine corpus endometrial carcinoma patients (93). Here, COMMD6 is linked to uveal melanoma.